# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Josh Schimmer reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and maintains $...
HC Wainwright & Co. analyst Douglas Tsao maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and raises the pri...
Oppenheimer analyst Leland Gershell reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and lowers the pric...
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(0.94) per share which missed the analyst consensus estim...
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeut...
JP Morgan analyst Jessica Fye maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and raises the price targe...